ACADIA Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $342,291 | $307,959 | $268,062 | $283,989 |
Gross Profit | 307,201 | 279,643 | 243,271 | 257,764 |
EBITDA | 80,439 | 32,356 | 6,974 | 29,243 |
EBIT | 71,718 | 29,199 | 3,981 | 26,319 |
Net Income | 53,524 | 31,500 | 3,637 | 273,568 |
Net Change In Cash | 342,291 | 307,959 | 268,062 | 283,989 |
Free Cash Flow | 10,263 | 124,461 | 28,769 | -52,736 |
Cash | 322,365 | 384,985 | 282,212 | 177,695 |
Basic Shares | 175,466 | 172,851 | 172,706 | 171,359 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $1,071,505 | $957,797 | $726,437 | $517,235 |
Gross Profit | 982,507 | 875,956 | 680,706 | 507,069 |
EBITDA | 150,664 | 100,162 | -45,484 | -221,570 |
EBIT | 138,904 | 84,279 | -51,036 | -223,596 |
Net Income | 391,000 | 226,451 | -61,286 | -215,975 |
Net Change In Cash | 1,071,505 | 957,797 | 726,437 | 517,235 |
Free Cash Flow | 105,146 | 157,196 | -23,348 | -114,035 |
Cash | 177,695 | 319,589 | 188,657 | 114,846 |
Basic Shares | 171,359 | 166,362 | 163,819 | 161,683 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $0.31 |
2026-06-30 | $0.18 |
2026-03-31 | $0.02 |
2025-12-31 | $0.13 |